Altimmune share price logo

Altimmune

NASDAQ: ALT

Small Cap

$2.04

-0.08

(-3.77%)

as on

Altimmune Stock Performance

as on October 27, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $2.02
    $2.15
    downward going graph

    0.98%

    Downside

    5.39%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.06
    $6.44
    downward going graph

    -0.98%

    Downside

    215.68%

    Upside

    downward going graph

Altimmune share price movements today

Previous Close
$2.12
Open
$2.13
Volume
3.2M
Market Cap
$412.4M
Day's Low - High
$2.02 - $2.15
52 Week Low - High
$2.06 - $6.44

Altimmune Historical Returns

1 Month Return
-30.72 %
3 Month Return
-23.47 %
1 Year Return
-46.33 %
3 Year Return
-8.62 %
5 Year Return
-81.21 %

Altimmune Stock Fundamentals & Key Indicators

Check Altimmune market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$412.4M

EPS (TTM)

-0.78

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.72

Industry PE ratio

-7.96

PEG Ratio

-0.06

EBITDA

-92.6M

Revenue (TTM)

31.0K

Profit Margin

-48306.45%

Return On Equity TTM

-31.41%

Altimmune vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Altimmune with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Altimmune image
Altimmune
StrongBuy$412.4M-81.21%-2.72-48306.45%0.00%
Moderna image
Moderna
Neutral$79.9B-42.12%-25.08-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$132.8B184.64%30.2586.04%0.00%
Regeneron image
Regeneron
Buy$82.9B35.95%19.2284.86%0.46%

Stock Returns calculator for Altimmune Stock including INR - Dollar returns

The Altimmune stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Altimmune investment value today

Current value as on today

₹55,735

Returns

-₹44,265

(-44.27%)

Returns from Altimmune Stock

-₹48,354 (-48.35%)

Dollar Impact

₹4,089 (+4.09%)

Analyst Recommendation on Altimmune Stock

Based on 4 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 4 analysts, 75% of analysts recommend a 'BUY' rating for Altimmune. Average target price of $17.11

Altimmune Share Price Target

Get share price movements and forecasts by analysts on Altimmune.

What analysts predicted

88.08%UPSIDE

Target Price

$17.11

Current Price

$2.04

Analyzed by

4 Analysts

High

$20

Target

$17.11

Low

$10

Altimmune target price $17.11, a slight upside of 88.08% compared to current price of $2.04. According to 4 analysts rating.

Indian Investors' Interest in Altimmune Stock

Search interest for Altimmune Stock has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-14% versus previous 30 day period

Altimmune Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
0
0
0
0
0
0
-
-
Gross Profit
0
0
0
0
0
0
-14
0
0
0
Operating Income
-26
-26
-24
-24
-21
-22
-20
-28
-24
-26
EBITDA
-24
-24
-22
-23
-20
-21
-18
-26
-21
-26
Interest Expense
0
0
0
0
0
0
0
0
1
1
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-24
-24
-22
-23
-20
-22
-19
-27
-22
-22
Income Tax Expense
-
-
-
-
0
-
-
-
-
-
Net Income
-24
-24
-22
-23
-19
-22
-19
-27
-22
-22
Net Profit Margin
-2040.00%
100.00%
100.00%
100.00%
100.00%
100.00%
-299100.00%
100.00%
0.00%
0.00%

Altimmune Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Mar 2019
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
10
5
8
4
0
0
0
0
Gross Profit
-18
-8
5
-25
4
0
0
0
0
Operating Income
-52
-42
-21
-54
-96
-87
-95
-103
-94
EBITDA
-51
-44
-20
-38
-96
-84
-87
-94
-87
Interest Expense
0
0
0
0
0
0
0
0
1
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-52
-45
-20
-43
-97
-84
-88
-95
-88
Income Tax Expense
-5
-6
0
5
-
0
-
-
0
Net Income
-46
-39
-20
-49
-97
-84
-88
-95
-88
Net Profit Margin
-44249.39%
-78.68%
100.00%
-309.40%
100.00%
100.00%
100.00%
100.00%
100.00%

Altimmune Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-24
-24
-22
-23
-19
-22
-19
-27
-22
-22
Operating Cash Flow
-16
-18
-27
-18
-16
-19
-11
-19
-20
-24
Investing Cash Flow
-39
-3
1
13
-5
101
-149
-79
-3
-221
Financing Cash Flow
0
0
0
10
34
52
39
81
78
211
Change in Cash
-56
-21
-25
5
12
134
-121
-17
53
-34

Altimmune Annual Cash Flow

All numbers in Millions USD

Dec 2017
Mar 2019
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-46
-39
-20
-49
-97
-84
-88
-95
-88
Operating Cash Flow
-20
-9
-9
-34
-78
-62
-75
-79
-67
Investing Cash Flow
13
-1
-28
-72
87
-73
13
-28
-132
Financing Cash Flow
15
32
12
213
65
56
86
10
206
Change in Cash
9
22
-25
106
74
-79
24
-98
6

Global Institutional Holdings in Altimmune

Check out the Institutions with significant holdings in Altimmune.

Funds
Holdings
Vanguard
4.84%
iShares
4.79%
Andreas Halvorsen
3.44%
Peter Kolchinsky
3.34%
VANGUARD INDEX FUNDS
2.84%
See all

Insights on Altimmune

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 5.0K → 26.0K (in $), with an average increase of 80.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 163.4% return, outperforming this stock by 172.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 648.3% return, outperforming this stock by 694.6%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, ALT stock has moved down by -4.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -22.56M → -22.82M (in $), with an average decrease of 1.2% per quarter

About Altimmune

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
OrganisationAltimmune
Headquarters910 Clopper Road, Gaithersburg, MD, 20878, US
IndustryBiotechnology
CEOJerome Benedict Durso

Key Management of Altimmune

Name

Title

Ms. Robin E. Abrams J.D.

Chief Legal Officer & Corporate Secretary

Mr. Gregory L. Weaver CPA, M.B.A.

Chief Financial Officer

Mr. Richard Menziuso

VP, Global Controller & Principal Accounting Officer

Mr. Tony Blandin B.S.

Vice President of Quality & Compliance Management

Mr. Bertrand Georges Ph.D.

Chief Technology Officer

Mr. Luis Sanay C.F.A.

Vice President of Investor Relations

Mr. Raymond M. Jordt M.B.A., M.S.

Chief Business Officer

Mr. Jerome Benedict Durso

Chairman, CEO & President

Dr. M. Scot Roberts Ph.D.

Chief Scientific Officer

Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.

Chief Medical Officer

FAQs

What is Altimmune share price today?

Altimmune share price today is $2.04 as on at the close of the market. Altimmune share today touched a day high of $2.15 and a low of $2.02.

What is the 52 week high and 52 week low for Altimmune share?

Altimmune share touched a 52 week high of $6.44 on and a 52 week low of $2.06 on . Altimmune stock price today i.e. is closed at $2.04,which is 68.32% down from its 52 week high and -0.97% up from its 52 week low.

What is Altimmune's market capitalisation today?

Altimmune market capitalisation is $0.00T as on .

How to invest in Altimmune Stock (ALT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Altimmune on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Altimmune Stock (ALT) from India?

Indian investors can start investing in Altimmune (ALT) shares with as little as ₹95.20999908447266 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.10 in Altimmune stock (as per the Rupee-Dollar exchange rate as on ). Based on Altimmune share’s latest price of $2.04 as on October 27, 2026 at 1:29 am IST, you will get 4.9020 shares of Altimmune. Learn more about fractional shares .

What are the returns that Altimmune has given to Indian investors in the last 5 years?

Altimmune stock has given -81.21% share price returns and 26.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?